14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LFCR vs AKRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Lifecore Biomedical, Inc. (LFCR) on higher Unified Composite conviction (60.0/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 8–2 (led by Growth & Scale, Profitability & Quality), while LFCR wins 4–2 across the 6-pillar growth and valuation breakdown. LFCR trades at $6.39 (8.7x Forward P/E, -6.2% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: AKRO earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. LFCR 58.2/100 HOLD) and 0.90β · 2% Vol risk profile, whereas LFCR leads top-line expansion (-18.6% YoY revenue growth, 2.66x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LFCR vs AKRO. Trailing 12-month operating profitability (LFCR -6.2% vs AKRO 0.0%) and valuation multiples (LFCR 8.7x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LFCR vs AKRO Key Questions & Quantitative Answers
As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Lifecore Biomedical, Inc. (LFCR) on higher Unified Composite conviction (60.0/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 8–2 (led by Growth & Scale, Profitability & Quality), while LFCR wins 4–2 across the 6-pillar growth and valuation breakdown. LFCR trades at $6.39 (8.7x Forward P/E, -6.2% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: AKRO earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. LFCR 58.2/100 HOLD) and 0.90β · 2% Vol risk profile, whereas LFCR leads top-line expansion (-18.6% YoY revenue growth, 2.66x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
AKRO leads the Growth & Scale pillar: LFCR posts -18.6% YoY revenue growth and +0.0% YoY earnings growth on $106M TTM revenue (27.5% gross margin, -6.2% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LFCR generates $106M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, LFCR deploys 33.7% of Rev ($36M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.
LFCR screens cheaper on headline valuation multiples. LFCR trades at 8.7x Forward P/E, 8.7x Trailing P/E, 2.66x PEG, and 3.6x EV/Revenue (6.5% FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LFCR (-76.4% ROE) versus AKRO (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, LFCR carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.44β · 9% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.